Commonwealth Scientific & Industrial Research Organisation provides scientific and industrial research services. It plays a role in collaboration within the Australian national innovation system and as an advisor to government, industry and the community. The company was founded in 1916 and is headquartered in Canberra, Australia.

Ambrx is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. These include next generation antibody drug conjugates (ADCs), bispecifics, targeted immuno-oncology therapies, novel cytokines to modulate the immune system, and long-acting therapeutic peptides for metabolic and cardiovascular disease. Ambrx is advancing a robust portfolio of clinical and preclinical programs designed to optimize efficacy, safety and ease of use, in multiple therapeutic areas, including its lead product candidate ARX788.

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Marker Gene Technologies, Inc. engages in provision of biochemical, reagents, and kits for the biotechnology industry. It explores, develops and manufactures products and systems that utilize marker, reporter genes and also provides development of new uses for these genes and promote systems to help treat human diseases as well as other biotechnology research and industrial applications. The company was founded in 1993 and is headquartered in Eugene, OR.

Syngenta AG is a global company that produces agrochemicals and seeds and is based in Basel, Switzerland. As a biotechnology company, it conducts genomic research. It was formed in 2000 by the merger of Novartis Agribusiness and Zeneca Agrochemicals. As of 2014 Syngenta is the world’s largest crop chemical producer As of 2009 it ranked third in seeds and biotechnology sales. Sales in 2015 were approximately US$13.4 billion, over half of which were in emerging markets. It is owned by ChemChina, a Chinese state-owned enterprise.

Watline Avenue | Microbix Biosystems Inc. Microbix Biosystems Inc. develops biological products and technologies. The Company was founded in 1988 as a producer of Infectious Disease Antigens, primarily for the diagnostics market. The Company invests in the virology business to build capacity and develop new products to address emerging market opportunities, while enhancing manufacturing and laboratory capabilities and technologies. Building on expertise in virology and protein biochemistry, the Company developed a pipeline of selected biological technologies including VIRUSMAX (Influenza Virus Yield Enhancement Technology), LumiSort™ (Semen Sexing Technology) and the thrombolytic drug, Kinlytic® (Urokinase). Funded by income from the antigen business, the pipeline products take aim at large market opportunities. With Microbix’ core competencies in the Infectious Disease Antigen business, including cell culture, molecular biology, and a GMP quality system, the pipeline products build on Microbix’ strength.

Atomic Energy of Canada Limited (AECL; French: Énergie atomique du Canada limitée (EACL)) is a Canadian federal Crown corporation and Canada's largest nuclear science and technology laboratory. AECL developed the CANDU reactor technology starting in the 1950s, and in October 2011 licensed this technology to Candu Energy (a wholly owned subsidiary of SNC-Lavalin).

AlphaVax develops a range of vaccine products for infectious diseases, biodefense, and cancer. It uses alphavaccine vector platform technology to generate a portfolio of vaccine candidates for infectious disease prevention and cancer immunotherapy. AlphaVax was founded by Jonathan F. Smith and is based in Durham, North Carolina.

Prolexys Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering small molecule drugs that act at novel therapeutic targets. The Company's therapeutic focus is on cancer and cardiovascular indications. Prolexys scientists have exploited proprietary proteomics-related techniques to rapidly and accurately identify drug candidates that interact with targets of interest.\nThe result of targeted drug discovery work at Prolexys is a pipeline of product candidates with high value in areas of unmet medical need. Lead programs include:\na) Solid tumor oncology program with a small molecule clinical candidate with selective anti-tumor activity,\nb) The colon cancer program with novel small molecule compounds targeting the beta-catenin signaling cascade and\nc) HSP20 antagonists, identified as protein interaction inhibitors from targets validated in asthma and vasorelaxation.

Bayer Corp. manufactures and markets pharmaceutical, healthcare, nutrition and materials products. The firm offers consumer care, diagnostics, diabetes and animal health products. It also provides material science products, which include coating, adhesive and sealant raw materials polycarbonates polyurethanes and thermoplastic polyurethane elastomers. The company was founded in 1973 and is based in Whippany, NJ.

Glaucus Proteomics BV develops antibody and protein array technologies to optimize drug development and disease management. The company was founded in 2000 and is headquartered in Utrecht, the Netherlands.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA.

Develops medicines and healthcare products using polymer technologies

Novartis Pharma GmbH engages in the production and sale of pharmaceutical products. The firm establishes and operates institutes for the development of medicinal products. It also conducts research and development in the field of pharmacy. The company was founded by Johann Rudolf Geigy-Gemuseus in 1758 and is headquartered in Vienna, Austria.

Sangamo BioSciences is a clinical stage biopharmaceutical company involved in gene therapy that is researching ways of commercializing Zinc finger nucleases which modify a cell's DNA at an exact location thereby correcting or disrupting a specific gene. Sangamo BioSciences' lead therapy, SB-728, is a potential functional cure for HIV/AIDS. SB-728 works by removing some of the immune cells from the patient's blood that HIV attacks. The blood is sent to a lab which applies the SB-728 treatment to the patient's immune cells. The treatment removes the protein gateway on the immune cells that HIV needs to infect. The treated cells are then infused back into the patient whereby they reproduce and take over as HIV attacks and kills the non-treated cells. The treated, resistant cells thereby control the HIV infection and thus cures the patient from opportunistic infections that result from HIV. Recent published data further support the company's ongoing progress which has been described as "a major step toward immunological functional control of HIV."

Zhejiang Yinlu New Material Co., Ltd., established on 2010-03-22, Business scope includes annual output:Synthetic resins containing flammable solvents,paint,Auxiliary material,Paint and other products[Closed cup flash point ≤60ºC]6000Ton(Acrylic resin coating2000Ton,Polyurethane resin coating300Ton,amino resin coating600Ton,Epoxy paint100Ton,Alkyd Coatings500Ton,gravure ink200Ton,specialty ink300Ton,paint thinner1900Ton,7110A polyurethane curing agent80Ton,epoxy paint curing agent20Ton).Serve:Loading and unloading.Sales:Wujinjiaodian,electronic product,Electronics and Components,Instrumentation,Computers and software and auxiliary equipment,building materials(Except hazardous chemicals and precursor chemicals),Equipment;Import and export of goods and technology(law,Except where prohibited by administrative regulations);Install:household appliances(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)